关键字不能为空!

Enter

Home » Research » International Cooperation

International Cooperation

2017-12-11

PKUPH attaches great importance to international cooperation in scientific research and has carried out collaborative scientific research programs in different fields with multiple international universities and medical organizations. International cooperation in scientific research has efficiently promoted discipline development and personnel training of the hospital.
A program collaboratively carried out by Prof. LI Zhanguo of Department of Rheumatology and Immunology and Karolinska Institute (Sweden), "A Study on Differences between Han People and White People in Hereditary Features and Environmental Influencing Factors of Rheumatic Arthritis", is provided with financial support by Funds for International (Inter-regional) Cooperation and Exchange of National Natural Science Foundation. The program focuses on hereditary correlation and difference of rheumatic arthritis (RA) in Chinese Han people and white people, expecting to discover common predisposing genes of RA in different populations. RA predisposition differences between different populations and possible molecular mechanisms of relevant predisposing genes participating in pathogenesis of RA are investigated to provide reference for understanding hereditary features of RA and seeking new therapeutic targets. 
Prof. WEI Lai of Hepatology Institute and experts of University of Michigan have carried out a collaborative study in translational and clinical medicine, "A Study on Markers for Predicting Progression of Hepatitis C". The two parties will construct two cohorts of patients with chronic HCV infection, one in Peking University Health Science Center and the other in University of Michigan Medical School. The study will be carried out on both cohorts following a standard protocol. This study is intended to discover hereditary markers that can be used to predict disease progression of patients with chronic HCV infection and also to discover and validate markers in blood for hepatic fibrosis and early HCC.
Prof. JI Linong of Department of Endocrinology and experts of University of Michigan have jointly carried out a research program for "Data Comparison of Food Frequency Questionnaires and 24-Hour Dietary Recall of Chinese People in Pinggu District of China". In this study, the two parties will jointly carry out preliminary investigation of research on diabetes mellitus and hepatic adipose infiltration, validate feasibility of the nutrition questionnaire system, and develop and test a food frequency questionnaire that can relatively accurately reflect dietary intake of residents in Pinggu District.
Prof. HAN Fang of Department of Respiratory Medicine and researchers of Max Planck Institute for Psychiatry (Germany) and Charite University Medical Center in Berlin have carried out a program for joint establishment of a "Sino-German Joint Center for Sleep Medicine". Sponsored by Sino-German Center of National Natural Science Foundation of China, the program is the 14th joint center financially supported by Sino-German Center and also the only joint center in the field of clinical research. It aims to establish a relatively stable collaborative scientific research team for the purpose of enhancing Sino-German scientific cooperation and, with Peking University People's Hospital in China and Max Planck Institute for Psychiatry, Munich Mental Health Center and Charite University Medical Center in Berlin in Germany as the core, attract more scientific research institutes and scientists from China and Germany to participate in the program; cultivate talents in sleep medicine, young talents in particular; introduce Germany's experience in construction of the sleep medicine discipline and enhance China's discipline construction of sleep medicine; create an open and high-level international collaborative research platform and use China's abundant case resources to carry out collaborative studies to lay a foundation for further international cooperation and exchange in the future.

Prof. WEI Lai of Peking University Hepatology Institute and experts of Agency for Science, Technology and Research, Institute of Molecular & Cell Biology in Singapore have jointly carried out a research program for "Clinical Database Collagen Quantification and Classification/Prediction Platform for Liver Tissue Fibrosis ". Liver fibrosis is a formation of excess fibrous connective tissues in liver, also known as scarring. It is a developmental stage before liver cirrhosis. Liver cancer is also reported to be associated with different degrees of liver fibrosis. There are two major causes of liver fibrosis, i.e. infective (such as hepatitis C virus) and non-infective (such as fatty liver). The liver fibrosis will impair patients’ liver functions, reduce their quality of life and cause the complexity of life risk. The liver fibrosis of some of patients is revocable and some are not, while the mechanism is not clearly yet. 20%-30% of liver fibrosis patients will develop to liver cirrhosis. It is important to identify the irrevocable liver fibrosis patients and predict the risk of liver cirrhosis in clinic for earlier medical interference. The traditional methods are not able to clearly quantify the collagen structure in liver tissue. We propose a platform, Fibro Quant, to use a novel imaging technique combined with a biomedical imaging informatics method for the structural quantification and evaluation of liver fibrosis. Our solution is faster, simpler, more reliable and accurate. We will focus on HCV and fatty liver in this study. The clinical samples and data will be collected. The liver biopsy will be scanned. Medical image processing solution will be designed to transform the acquired images into numerical features. Mathematical models will be established for classification and prediction. The structural difference of collagen between the irrevocable and revocable cases will provide new insight of the unknown mechanism. The separation of these two types of patients has significant clinical value. The accurate prediction of the risk of cirrhosis of patients is a step to optimize our national medical resources. Our research outcome will be commercialized and impact the healthcare of liver disease in both countries. 

Dr. Hong-Hu Zhu of Department of hematology of Peking University People’s Hospital and Prof. Lo-Coco F of The University of Rome Tor Vergata of Italy, and Prof. Vikram M of The Christian Medical College of India have carried out a cooperation in scientific research projects, which is funded by the National  Key  R&D  Program  of  China (No. 2016YFE0202800). It aims to establish a relatively stable collaborative scientific research team for the purpose of enhancing scientific cooperation on the Traditional China Medicine arsenic for the treatment of acute promyelocytic leukemia; cultivate talents in acute promyelocytic leukemia; introduce Chinese experience in fighting acute promyelocytic leukemia using oral arsenic; create an open and high-level international collaborative research platform to use China's unique oral arsenic and the innovative outpatient treatment model for acute promyelocytic leukemia. This collaborative study will promote the strategy of China “the Belt and Road” and step out of the first step in this field.